Latest Period
Q1 2026
Security Snapshot
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) Institutional Ownership
CUSIP: 45719W205
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
97
Shares (Excl. Options)
106,881,231
Price
$1.68
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value
- Symbol
- IKT on Nasdaq
- Shares outstanding
- 140,000,283
- Price per share
- $1.88
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 106,881,231
- Total reported value
- $179,529,138
- % of total 13F portfolios
- 0%
- Share change
- +7,456,859
- Value change
- +$11,673,673
- Number of holders
- 97
- Price from insider filings
- $1.88
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 45719W205.
- 97 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 73 to 97 between Q4 2025 and Q1 2026.
- Reported value moved from $218,151,569 to $179,529,138.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 97 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 45719W205?
CUSIP 45719W205 identifies IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45719W205:
Significant Owners of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $25,439,441 | 14,054,940 | Commodore Capital LP | 31 Mar 2026 | |||
| ADAR1 Capital Management, LLC | 9.9% | 0% | $25,086,651 | +$2,113,430 | 13,860,028 | +9.2% | ADAR1 Capital Management, LLC | 31 Mar 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 11% | -26% | $26,037,930 | +$4,137,930 | 13,018,965 | +19% | Sands Capital Life Sciences Pulse Fund II, L.P. | 31 Dec 2025 |
| PERCEPTIVE ADVISORS LLC | 8.9% | -11% | $22,870,934 | -$327,190 | 12,635,875 | -1.4% | Perceptive Advisors LLC | 31 Mar 2026 |
| Fairmount Funds Management LLC | 9.9% | 0% | $24,922,202 | +$10,885,052 | 12,461,101 | +78% | Fairmount Funds Management LLC | 31 Dec 2025 |
| Trails Edge Capital Partners, LP | 6.1% | +20% | $14,583,794 | +$3,460,986 | 8,057,345 | +31% | Trails Edge Capital Partners, LP | 31 Mar 2026 |
| Nantahala Capital Management, LLC | 5.7% | -23% | $14,075,832 | +$3,478,584 | 7,037,916 | +33% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 5% | $7,975,554 | 3,529,006 | Armistice Capital, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 97 institutional investors reported holding 106,881,231 shares of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT). This represents 76% of the company’s total 140,000,283 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) together control 73% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 9.3% | 13,018,965 | 0% | 5.2% | $21,871,861 |
| Soleus Capital Management, L.P. | 7.8% | 10,875,000 | 0% | 0.74% | $18,270,000 |
| Fairmount Funds Management LLC | 6.2% | 8,625,000 | 0% | 1% | $14,490,000 |
| Trails Edge Capital Partners, LP | 5.8% | 8,057,345 | +30% | 3.2% | $13,536,340 |
| BlackRock, Inc. | 4.5% | 6,303,433 | +91% | 0% | $10,589,768 |
| Blackstone Inc. | 4.2% | 5,938,276 | 0% | 0.04% | $9,976,304 |
| Siren, L.L.C. | 4.2% | 5,850,000 | 0% | 0.27% | $9,828,000 |
| Commodore Capital LP | 3.9% | 5,397,488 | 0% | 0.52% | $9,067,780 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 4,450,665 | 0% | 0% | $7,477,117 |
| Saturn V Capital Management LP | 2.8% | 3,863,445 | +0.17% | 1.2% | $6,490,588 |
| Kalehua Capital Management LLC | 2.7% | 3,821,890 | +118% | 4.5% | $6,420,775 |
| Spruce Street Capital LP | 2.6% | 3,581,603 | 0% | 1.4% | $6,017,093 |
| Squadron Capital Management LLC | 2.5% | 3,500,000 | -17% | 2.4% | $5,880,000 |
| MILLENNIUM MANAGEMENT LLC | 2.1% | 2,928,077 | +1624% | 0% | $4,919,169 |
| Nantahala Capital Management, LLC | 1.9% | 2,701,863 | -31% | 0.28% | $4,539,130 |
| PERCEPTIVE ADVISORS LLC | 1.7% | 2,315,000 | -57% | 0.08% | $3,889,200 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 2,170,186 | +92% | 0% | $3,646,792 |
| STATE STREET CORP | 1.2% | 1,685,816 | +204% | 0% | $2,832,171 |
| SummitTX Capital, L.P. | 1.1% | 1,524,536 | 0.08% | $2,561,220 | |
| Integral Health Asset Management, LLC | 0.96% | 1,350,000 | -23% | 0.12% | $2,268,000 |
| CITADEL ADVISORS LLC | 0.79% | 1,102,585 | -11% | 0% | $1,852,343 |
| Stonepine Capital Management, LLC | 0.68% | 957,202 | -59% | 1.4% | $1,608,099 |
| TWO SIGMA INVESTMENTS, LP | 0.61% | 847,611 | 0% | $1,423,986 | |
| NORTHERN TRUST CORP | 0.51% | 718,800 | +123% | 0% | $1,207,584 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.44% | 617,730 | 0% | 0% | $1,037,786 |
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 106,881,231 | $179,529,138 | +$11,673,673 | $1.68 | 97 |
| 2025 Q4 | 106,415,262 | $218,151,569 | +$72,128,708 | $2.05 | 73 |
| 2025 Q3 | 54,964,771 | $89,043,214 | +$712,913 | $1.62 | 53 |
| 2025 Q2 | 54,512,097 | $106,299,597 | +$5,482,917 | $1.95 | 48 |
| 2025 Q1 | 51,462,756 | $112,702,942 | +$3,027,389 | $2.19 | 47 |
| 2024 Q4 | 50,059,308 | $162,691,896 | +$161,164,562 | $3.25 | 31 |
| 2024 Q3 | 860,232 | $1,118,330 | +$30,199 | $1.30 | 11 |
| 2024 Q2 | 836,496 | $1,021,038 | +$723,392 | $1.21 | 12 |
| 2024 Q1 | 205,558 | $443,782 | -$62,190 | $2.16 | 12 |
| 2023 Q4 | 235,004 | $298,925 | -$271,105 | $1.27 | 11 |
| 2023 Q3 | 429,662 | $597,627 | -$496,803 | $1.39 | 13 |
| 2023 Q2 | 747,138 | $2,693,647 | +$2,394,678 | $3.61 | 14 |
| 2023 Q1 | 82,817 | $54,460 | +$54,460 | $0.66 | 1 |